INSTITUTE OF IMMUNOLOGY AND GENETICS

Institute of Immunology and Genetics, Pfaffplatz 10, 67655 Kaiserslautern

LABORATORY MEDICINE
Dr. med. Bernhard Thiele
Prof. Dr. med. Jens Verheyen

HUMAN GENETICS
Prof. Dr. med. Wolfram Henn
Dr. med. Anne-Karin Kahlert

Phone: +49(0)631/31670-0 Fax: +49(0)631/31670-20
office@immungenetik-kl.de | www.immungenetik-kl.de

Physician information:	**Patient:**

Request form for oncological laboratory diagnostics

Diagnosis:

☐ CML ☐ B-CLL ☐ B-ALL
☐ MPN ☐ B-NHL ☐ T-ALL
☐ MDS ☐ T-NHL ☐ CMML
☐ AML ☐ MM/Plasmocytoma
☐ _____

Level of therapy:

☐ Initial diagnosis
☐ Control
☐ Recurrence
☐ after BMT, donor ☐ ♀ ☐ ♂
☐ _____

Type of sample:

☐ Peripheral blood
☐ Bone marrow
☐ _____

Other clinical comments:

Sampling date / time:	**Signature:**

Please prepare the following documents and samples for shipment:

- **Request form**
- **Sample labeled with patient name and date of birth:**
  - **Karyogram and FISH: at least 5ml heparin blood resp. 3ml heparin bone marrow**
  - **Molecular genetics: 3ml EDTA blood resp. 3ml EDTA bone marrow**
- **Declaration of consent signed by the patient according to the German Genetic Diagnostics Act (GenDG) (only required for analyses under the heading "Other tests")**

Patient name: **Date of birth:**

KARYOGRAM

☐ Microscopic chromosome analysis

B-NHL/CLL

☐ Karyogram – complex karyotype (B-CLL)

☐ MG - TP53

☐ MG - IGHV (clonality, hyper mutation status (CLL))

☐ FISH - panel B-CLL

☐ MG – gene analysis B-CLL (e.g. for therapy indication) (TP53, BIRC3, NOTCH1, SF3B1)

☐ FISH - panel Non-Hodgkin-Lymphoma (B-NHL)

☐ MG - specific mutation analysis - Lymphoma panel (BRAF, MYD88, NRAS, SF3B1, MYC)

Multiple Myeloma / Plasmocytoma

☐ FISH - panel MM

☐ MG - specific mutation analysis MM panel (BRAF, NRAS, KRAS)

Waldenstrom's disease

☐ FISH - panel M. Waldenstrom

☐ MG - gene analysis (CXCR4, MYD88)

Burkitt's lymphoma

☐ FISH - panel Burkitt's lymphoma

DLBCL

☐ FISH - panel DLBCL

Follicular lymphoma

☐ FISH - panel Follicular lymphoma (incl. t(14;18))

☐ PCR - t(14;18) IGH::BCL2

Mantle cell lymphoma

☐ FISH - panel Mantle cell lymphoma (incl. t(11;14))

☐ PCR - t(11;14) CCND1::IGH

Marginal zone lymphoma

☐ FISH - panel Marginal zone lymphoma

Hairy cell leukemia

☐ FISH - panel Hairy cell leukemia

T-cell lymphoma

☐ FISH - panel T-cell lymphoma

Molecular genetic testing (cross-diagnosis)

☐ MG - pan Myelo/Lympho panel (gene analysis) (incl. ASXL1, BRAF, CBL, CSF3R, DDX41, DNMT3A, EZH2, IDH1, IDH2, JAK2, MYD88, NRAS, NOTCH1, RUNX1, SF3B1, SRSF2, STAG2, TET2, TP53, U2AF1, ZRSR2)

MPN/CML

☐ Karyogram - (BM control, diagnosis)

☐ FISH - high-risk cytogenetic alterations

☐ t(9;22) BCR::ABL1 (qualitative, diagnostic)

☐ t(9;22) BCR::ABL1 (quantitative, therapy monitoring)

☐ abl1 sequencing (TKI resistance resp. therapy failure)

☐ atypical CML (aCML) - gene analysis (SETBP1, ETNK1)

MPN

☐ Karyogram (PMF, CMML, CML)

☐ Characteristic chromosomal changes FISH (diagnostics/risk stratification)

☐ MG - diagnostics stage 1 - JAK2 V617F, CALR, MPL

☐ MG - diagnostics stage 2 - specific mutation analysis (incl. CBL, IDH1, IDH2, SRSF2, SF3B1, U2AF1)

☐ MG - diagnostics stage 3 - gene analysis (TP53, RUNX1, ASXL1)

☐ Polyglobulia, suspicion of PV (JAK2 exon 12 -14)

☐ PV - JAK2 V617F allele frequency - follow up

MPN - Eosinophilia (exclusion diagnostics e.g. in CMML)

☐ Characteristic chromosomal rearrangements FISH - PDGFRα and β, FGFR1, JAK2

MDS

☐ Chromosomal aberrations (karyogram and FISH)

☐ MG - diagnostics stage 1 - specific mutation analysis (inkl. SF3B1, SRSF2, SETBP1, IDH1/2, U2AF1)

☐ MG diagnostics stage 2 - gene analysis (TET2, ASXL1, RUNX1, TP53, DNMT3A)

MPN - CMML

☐ Cytogenetics

☐ MG - gene analysis (TP53, RUNX1, ASXL1, TET2)

AML

☐ Classification/risk stratification for therapy planning karyogram, FISH panel, molecular genetics (incl. FLT3)

☐ Characteristic AML associated translocations FISH - (t(8;21); t(15;17), inv16)

ALL

☐ t(9;22) BCR::ABL1 (qualitative, diagnostic)

☐ ALL associated translocations - PCR PCR - t(1;19) PBX1::E2A, t(4;11) AF4::MLL

Other tests (declaration of consent is required)

☐ 5-FU toxicity screening (according to DGHO position paper)

☐ Hemochromatosis

☐ ß-thalassemia

☐ Sickle cell anemia

☐ Meulengracht's disease (UGT1A1*28)

Request for individual or special analyses: